Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma

L. Ratner, D. Rauch, H. Abel, B. Caruso, A. Noy, S. K. Barta, S. Parekh, Juan Carlos Ramos, R. Ambinder, A. Phillips, J. Harding, H. H. Baydoun, X. Cheng, S. Jacobson

Research output: Contribution to journalLetter

15 Scopus citations
Original languageEnglish (US)
Pages (from-to)e408
JournalBlood Cancer Journal
Volume6
DOIs
StatePublished - Mar 25 2016

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Ratner, L., Rauch, D., Abel, H., Caruso, B., Noy, A., Barta, S. K., Parekh, S., Carlos Ramos, J., Ambinder, R., Phillips, A., Harding, J., Baydoun, H. H., Cheng, X., & Jacobson, S. (2016). Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma. Blood Cancer Journal, 6, e408. https://doi.org/10.1038/bcj.2016.21